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OBJECTIVES: Alcoholism and alcohol abuse are widespread.
The economic consequences of these conditions in a managed-
care setting are largely unknown. METHODS: The direct eco-
nomic burden of alcoholism and alcohol abuse was estimated by
multiplying numbers of health care encounters and total health
care expenditures for alcohol-related conditions by corres-
ponding alcohol-attributable (i.e., etiologic) fractions (AAFs).
Alcohol-related conditions—including alcoholism and alcoholic
disorders, alcohol-related diseases, and alcohol-related injuries—
and AAFs were based on a published taxonomy developed for
the US Centers for Disease Control and Prevention (CDC).
Encounters and expenditures for the treatment of alcohol-related
conditions were estimated using 2004 health care claims data for
a random sample of 4 million managed-care plan members.
Direct economic burden was estimated on an overall basis and
by setting of care, for all members and by age and sex. RESULTS:
Alcohol-attributable expenditures totaled $216.2 million in
2004, or $5.4 million per 100,000 plan members, representing
3% of total health care expenditures during the year. Alcohol-
related diseases represented 55% of alcohol-attributable ex-
penditures; treatment of alcoholism and alcoholic disorders
constituted 38%. Hospitalizations represented 61% of attribut-
able expenditures, followed by hospital outpatient visits (13%),
physician ofﬁce visits (10%), and emergency room visits (5%).
Expenditures (per 100,000 plan members) were 1.6 times higher
for men than women, and increased with age. CONCLUSION:
The economic burden of alcohol-attributable expenditures in US
managed-care settings is substantial. Interventions directed at the
problem of alcoholism and alcohol abuse could yield consider-
able cost offsets.
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OBJECTIVES: One in every 13 US adults suffers from alcohol
dependence. Information on the economic burden these patients
place on health insurers is currently lacking. METHODS: Using
a large US health insurance database, we identiﬁed all patients
with a diagnosis of alcohol dependence syndrome in calendar
year (CY) 2004, as well as an age- and sex-matched group of
persons without such a diagnosis during this year (“comparison
patients”). Health care expenditures for the treatment of alcohol-
related conditions—including alcoholism and alcoholic disor-
ders, alcohol-related diseases, and alcohol-related injuries—were
tallied in CY2004 for alcoholics and comparison patients using
plan payments to providers. Expenditures were summarized
using means and 95% conﬁdence intervals (CI) estimated via
nonparametric bootstrapping. RESULTS: In a population of 4
million covered lives, 11,151 persons had one or more encoun-
ters with a diagnosis of alcohol dependence syndrome. Mean
(±SD) age of alcoholics was 40 (±14) years, and 67% were male.
Expenditures for alcohol-related conditions averaged $5945
(95%CI $5598–$6297) for alcoholics, versus $345 ($273–$438)
for comparison patients, a difference of $5600 ($5255–$5963).
Differences in mean expenditures increased with age (ages 65
years and older, $13,243), and were similar for men ($5771) and
women ($5255). CONCLUSION: Health care expenditures are
substantially higher among patients with encounters for alcohol
dependence in comparison with persons without evidence of this
problem.
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OBJECTIVES: The objective of this study was to analyze and
describe the drug cost development of the two most commonly
prescribed antidepressant drugs in Finland following the intro-
duction of generic substitution by pharmacists in April 2003.
METHODS: The prescription claims database of the Social
Insurance Institution of Finland was used to calculate the quar-
terly cost of reimbursements per user for citalopram and ﬂuox-
etine from January 2003 to June 2004. Price data were extracted
from the registry of the Association of Finnish Pharmacies for
April 2003 to April 2004. RESULTS: The quarterly cost of
citalopram and ﬂuoxetine per user to the Social Insurance Insti-
tution of Finland decreased by 45% and 48% respectively one
year following the introduction of generic substitution. The com-
panies which marketed the brand name drugs in Finland adopted
two contrasting pricing policies in response to generic substitu-
tion. A “pseudo-generic” version of citalopram, but not ﬂuoxe-
tine, was available throughout the study period. Regardless of
the pricing policy, cost savings of the same level were realized
for both patients and government. These cost reductions did not
lead to a corresponding increase in the use of citalopram or ﬂu-
oxetine. CONCLUSION: The introduction of generic substitu-
tion was followed by a decrease in price for the two most
commonly prescribed antidepressant drugs in Finland. High
price elasticity was observed within but not between active ingre-
dients. Price did not appear to guide antidepressant prescribing
by physicians.
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OBJECTIVES: To evaluate Attention Deﬁcit/Hyperactivity Dis-
order (ADHD) management among Hispanic (HIS) and non-
